Gilead Sciences, Inc. (GILD)

Over the past six months, Gilead Sciences' stock has experienced notable movements and been impacted by several events. The stock price increased by 1.97% over the last six months. Between October 2, 2024, and October 1, 2025, the share price increased by 31.17%. In Q4 2024, Gilead reported revenues of $7.57 billion, a 6.4% year-over-year increase, and EPS of $1.90, exceeding analyst expectations. In Q1 2025, total product sales were down 1% year-over-year due to fewer COVID-19 hospitalizations, but the base business grew 4%. In Q2 2025, Gilead reported solid quarterly results with non-GAAP operating income increasing and diluted earnings per share rising 20.9% year-over-year to $1.56. As of October 2025, analysts have a "Buy" consensus rating for GILD, with an average price target forecasting a 3.26% increase over the next year. In October 2025, Gilead announced settlement agreements to resolve patent litigation with generic pharmaceutical companies regarding its HIV treatment Biktarvy, stipulating that no generic versions are expected before April 1, 2036.

Gilead Sciences experiences demand seasonality for some of its key products. Veklury revenue has shown seasonality, with a "seasonality-driven revenue increase" observed in Q3 2024, but sales have also seen declines due to decreasing COVID-19 hospitalizations. The company's HIV business sales can also exhibit seasonality, with Q1 2025 HIV sales being down sequentially, consistent with "normal first quarter seasonality."

Gilead Sciences, Inc. is an American biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for life-threatening diseases. The company operates within the Healthcare sector, specifically in the Biotechnology and Drug Manufacturers - General industries. Gilead is a global leader in HIV treatment and prevention, with key products such as Biktarvy. They also have therapies for chronic liver diseases like hepatitis B and C. Gilead is expanding its presence in oncology through acquisitions and R&D, with products like Yescarta/Tecartus and Trodelvy. They are also active in developing treatments for inflammatory and respiratory diseases.

Gilead Sciences maintains a worldwide presence, operating in over 35 countries. Its global corporate headquarters are located in Foster City, California, USA. The company has significant operations and subsidiaries across Europe, the Americas, Asia-Pacific, the Middle East, and Africa. In the U.S., Gilead has additional key locations in El Segundo, Frederick, Raleigh, Santa Monica, La Verne, San Dimas, and Oceanside, California, supporting manufacturing, packaging, labeling, distribution, and clinical manufacturing.

In the past year, Gilead Sciences' brand reputation has been shaped by both positive recognition for its corporate responsibility efforts and challenges related to legal settlements. Gilead has been recognized for its ESG initiatives and public health commitments. However, Gilead agreed to a $202 million settlement with the U.S. government to resolve allegations that it used HIV speaker programs to provide kickbacks to doctors. Gilead Sciences was also facing thousands of consumer claims alleging that the company deliberately delayed the development of safer HIV drugs to maximize profits from older drugs.

Gilead Sciences, Inc. has a significant institutional ownership, with institutions holding approximately 72.62% to 88% of the company's stock. There are 3399 institutional owners and shareholders holding a total of 1,291,973,903 shares. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. The general public holds approximately 12% to 14% of the ownership, while insiders own less than 1% of the company's stock.